Options Brief: Cleveland BioLabs (CBLI)

Benzinga's Options & Vol Edge just made over 300% on IBM for its subscribers. See the next pick here before it's too late. Shares of Cleveland BioLabs CBLI are higher on the session by 3.10%, trading at $7.64. Overall call volume is now running at 2.95x the daily average, with 60% of all calls traded being purchases on the offer. 1,323 contracts have traded on the session so far. Cleveland BioLabs, Inc., incorporated on June 5 2003, is a biotechnology company focused on developing biodefense, tissue protection and cancer treatment drugs based on the concept of modulation of cell death for therapeutic benefit.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Options
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!